- In October 2023, Sanofi and Teva Pharmaceuticals announced a collaboration to develop TEV’574, a novel anti-TL1A therapy targeting inflammatory bowel diseases, specifically ulcerative colitis and Crohn's disease. This partnership underscores both companies' dedication to addressing unmet needs within the IBS treatment market, with TEV’574 currently undergoing clinical trials
- In June 2023, Ironwood Pharmaceuticals revealed that the U.S. Food and Drug Administration (FDA) had approved a new indication for LINZESS (linaclotide), allowing it to be used for treating functional constipation in pediatric patients aged 6 to 17 years. This approval broadens LINZESS's application in the IBS treatment market, where it is already effective for adults with constipation-predominant irritable bowel syndrome (IBS-C). This decision was based on favorable clinical trial outcomes, offering a vital option for children suffering from functional constipation and improving their quality of life
- In March 2022, Indegene, a technology-driven healthcare solutions provider, partnered with metaMe Health, the creator of Regulora, a Prescription Digital Therapeutics (PDT) company, to bring Regulora to market for treating abdominal pain associated with irritable bowel syndrome (IBS)
- In March 2021, Abbott collaborated with the Nutrition Society of India to enhance awareness among gastrointestinal patients by introducing dietary recommendations tailored to India. These recommendations address various gastrointestinal disorders, including functional constipation, chronic pancreatitis, peptic ulcers, and irritable bowel syndrome
- In January 2020, OrphoMed Inc. initiated a Phase II response-adaptive clinical trial (PREVAIL trial) for ORP-101, aimed at diagnosing irritable bowel syndrome with diarrhea (IBS-D). ORP-101 is a novel chemical compound developed to generate a substantial stable molecule featuring both partial agonist and complete antagonist receptor pharmacological properties
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (IBS-C and IBS-D), Indication (Irritable Bowel Syndrome with Constipation, Irritable Bowel Syndrome with Diarrhea, and Irritable Bowel Syndrome with alternating Constipation and Diarrhea), Product (Xifaxan, Linzess/Constella, Viberzi, and Amitiza), End Use (Hospitals and Clinics and Research Laboratories) – Industry Trends and Forecast to 2031
.
The Global Irritable Bowel Syndrome Treatment Market size was valued at USD 2.43 USD Billion in 2023.
The Global Irritable Bowel Syndrome Treatment Market is projected to grow at a CAGR of 9.32% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
